The JUPITER registry: One‐year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation

Silaschi, Miriam; Conradi, Lenard; Wendler, Olaf; Schlingloff, Friederike; Kappert, Utz; Rastan, Ardawan; Baumbach, Hardy; Holzhey, David; Eichinger, Walter; Bader, Ralf; Treede, Hendrik

doi:10.1002/ccd.27370

Cited by 60 publications

(32 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The initial search revealed a total of 5,208 potential articles. After exclusions, 19 reports remained for analysis (13 full texts , and 6 conference abstracts ). The PRISMA flow chart (Figure ) gives an overview of the literature search.…”

Section: Resultsmentioning

confidence: 99%

Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta‐analysis

Rawasia

Khan

Usman

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objective: The objective of this study was to analyze the available literature on using transcatheter aortic valve replacement (TAVR) for native aortic regurgitation (AR).Background: Surgical aortic valve replacement is the gold standard therapy for native AR. TAVR has emerged as an alternative approach in high-risk patients.Methods: MEDLINE, Scopus, and Cochrane CENTRAL were searched for reports of at least 5 patients undergoing TAVR for native AR. Outcomes included 30-day mortality, myocardial infarction, stroke, major bleeding, postprocedural moderate to severe AR, and device success.Pooled estimates were calculated using a random-effects model. Subgroup analysis and a metaregression were performed to study the effects of study level covariates on outcomes.Results: Nineteen studies (n =998 patients) were included. The rate of procedural success per Valve Academic Research Consortium -2 (VARC-2) criteria was 86.2% (78.8%-92.2%]. Thirty-day mortality was 11.9% (9.4%-14.7%). Subgroup analysis showed the use of new generation valves was associated with lower 30-day mortality (P = 0.02) and higher device success (P = 0.009) compared with early generation valves. There was no significant difference (P = 0.13) in the rate of 30-day mortality between patients receiving purpose-specific [8.2% (4.3%−13.1%); I2 = 0%] and nonpurpose specific valves [13.0% (8.2%-18.6%); I2 = 25%]. However, device success was higher (P = 0.02) in patients who received purpose-specific valves [96.3% (92.2%−98.9%); I2 = 0%] compared with nonpurpose specific valves [84.4% (75%−91.9%); I2 =46%].Conclusion: TAVR for native AR is associated with acceptable procedural success but increased early mortality. However, the safety and the efficacy of the procedure increased with newer valves. K E Y W O R D Saortic valve insufficiency, heart diseases, heart valve prosthesis

show abstract

Section: Resultsmentioning

confidence: 99%

Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta‐analysis

Rawasia

Khan

Usman

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…12) In addition, the feasibility of TAVI for patients with PAR was proven in several second-generation THV, including Evolut-R, 18) SAPIEN 3, 8) ACURATE neo, 9) Direct Flow Medical, 10) Lotus 11) et al The 1-year outcome of TAVI using a second-generation THV (J-Valve and Jenavalve) for PAR has been reported, and it presented a satisfactory outcome. 4,5,7) However, the long-term durability and efficiency of these devices were not demonstrated. Our study first reported the long-term follow-up of TAVI using J-Valve for PAR, and the dependable durability and Continuous variables were performed as mean ± standard deviation.…”

Section: Discussionmentioning

confidence: 99%

“…With the development of transcatheter heart valve (THV) devices and the technique of TAVI procedure, the second-generation THV has revolutionized the interventional treatment for PAR. 4,5) There are multiple reports presenting the feasibility of transcatheter approach for the treatment of PAR, 4,[6][7][8][9][10][11] and second-generation devices associated with an excellent procedural success rate and favorable perioperative outcomes compared with first-generation THV. In second-generation devices, the advantage is more pronounced on the "on-label" THVs (J-Valve and JenaValve) than "off-label" THVs.…”

Section: Introductionmentioning

confidence: 99%

Structural Valve Deterioration after Transcatheter Aortic Valve Implantation Using J-Valve: A Long-Term Follow-Up

Wang

et al. 2020

ATCS

View full text Add to dashboard Cite

Purpose: Our study aimed to investigate the structural valve deterioration (SVD) after transcatheter aortic valve implantation (TAVI) using J-Valve. Methods: In all, 14 patients with aortic stenosis (AS) and 4 patients with pure aortic regurgitation (PAR) were available in the study. Four-year follow-up was performed in all patients, and the clinical data and echocardiographic findings were recorded and analyzed. Results: All patients survived at the 4-year follow-up. There was no evidence of morphological SVD or prosthetic valve thrombosis in enrolled patients. None of the hemodynamic SVD occurred in patients with PAR. Mean gradients decreased from 61.93 ± 15.42 mm Hg (pre-TAVI) to 19.64 ± 9.16 mm Hg (discharge) in patients with AS (p <0.001); subsequently, a slight increase was observed in the mean trans-aortic gradient throughout follow-up (p = 0.967). Overall, in patients with AS, six individuals suffered moderate (3/14, 21.4%) or severe (3/14, 21.4%) hemodynamic SVD at 4-year follow-up. Conclusions: The limited number of cases provides a preliminary indication of the longterm efficacy of TAVI using J-Valve in patients with PAR. In patients with AS, although the higher rate of SVD was observed, the overall transcatheter heart valve (THV) hemodynamics remained stable over time after prosthetic valve implantation and the longterm durability of J-Valve was convincing.

show abstract

“…By now, only the JenaValve transcatheter heart valve (JenaValve Technology) and the J-Valve system (JC Medical) have been designed to address the morphological challenges in patients with AR, by providing a dedicated anchoring system in the aortic annulus in the absence of calcification. First clinical experiences reported a high procedural and device success rate for the JenaValve, leading to a CE Mark in Europe for the treatment of AR (38)(39)(40). In comparison to standard newer generation transcatheter heart valves, dedicated devices lead to a higher procedural success.…”

Section: Treatment Decision and Current Limitationsmentioning

confidence: 99%

Transcatheter Aortic Valve Implantation Current Indications and Future Directions

Winkel

Stortecky

Wenaweser

2019

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Degenerative heart valve disease is associated with significant morbidity and mortality and healthcare expenditures. Transcatheter heart valve repair and replacement has introduced a fundamental change in the therapeutic management and transcatheter aortic valve replacement (TAVR) has gained substantial popularity. Favorable results from randomized trials and large real world registries lead to TAVR being considered a standard procedure with high rates of procedural success and low rates of peri-procedural complications. This article aims to review the past evolution, summarize the available evidence, discuss current indications and limitations and venture a glimpse into the future of percutaneous interventions for aortic valve disease.

show abstract

The JUPITER registry: One‐year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation

Cited by 60 publications

References 24 publications

Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta‐analysis

Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta‐analysis

Structural Valve Deterioration after Transcatheter Aortic Valve Implantation Using J-Valve: A Long-Term Follow-Up

Transcatheter Aortic Valve Implantation Current Indications and Future Directions

Contact Info

Product

Resources

About